Open Access

Clinical presentation of severe COVID‑19 with heart failure: A single‑center retrospective study

  • Authors:
    • Xinling Liu
    • Tingting Liu
    • Rong Wan
  • View Affiliations

  • Published online on: March 11, 2024     https://doi.org/10.3892/etm.2024.12481
  • Article Number: 193
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The coronavirus disease‑19 (COVID‑19) pandemic has led to a global transformation in public health interventions. The present study aimed to evaluate the clinical features as well as the outcomes of severe heart failure (HF) among patients with severe COVID‑19. A single‑center observational study was carried out at The 904th Hospital of Joint Logistic Support Force (Wuxi, China) from November 2022 to April 2023, and a total of 210 patients diagnosed with severe HF were included. Among these patients, 128 patients had COVID‑19 whereas the remaining patients were not diagnosed with COVID‑19. The analysis entailed investigated pre‑existing medical records, that is, admission and discharge, laboratory values, neuroimaging, length of hospitalization, mortality and costs incurred by patients throughout the COVID‑19 pandemic from the records. All the 210 incorporated patients accomplished the follow‑up and it was established that there was no significant differences in baseline characteristics between HF combined with COVID‑19 and HF without COVID‑19 were affirmed (P>0.05). HF coupled with COVID‑19 infection demonstrated an increased risk of 30‑day mortality (28.91 vs. 14.63%; P=0.017), extended length of hospital stays (22.54±6.73 vs. 19.35±5.69; P<0.001) and higher expenses for hospitalization (P<0.001). Complications related to hospitalization, including pneumonia (76.56 vs. 35.37%; P=1.0x10‑4), respiratory failure (47.66 vs. 24.39%; P=0.001), pulmonary embolism (8.59 vs. 2.44%; P=0.031), deep vein thrombosis (30.47 vs. 14.63%; P=0.009), 7 days delirium (60.16 vs. 45.12%; P=0.033), multiple organ dysfunction syndrome (32.81 vs. 18.29%; P=0.021) and neurological deficits (30.47% vs. 17.07%, P=0.029) increased significantly. In conclusion, HF combined with COVID‑19, treatment and prognosis are getting worse. Enhancing preparedness for future COVID‑19 and other similar pandemics necessitates the comprehension of this to refine care provided to patients with HF (registration no. THH‑IPR‑20221101 on 01 November 2022).
View Figures
View References

Related Articles

Journal Cover

May-2024
Volume 27 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu X, Liu T and Wan R: Clinical presentation of severe COVID‑19 with heart failure: A single‑center retrospective study. Exp Ther Med 27: 193, 2024.
APA
Liu, X., Liu, T., & Wan, R. (2024). Clinical presentation of severe COVID‑19 with heart failure: A single‑center retrospective study. Experimental and Therapeutic Medicine, 27, 193. https://doi.org/10.3892/etm.2024.12481
MLA
Liu, X., Liu, T., Wan, R."Clinical presentation of severe COVID‑19 with heart failure: A single‑center retrospective study". Experimental and Therapeutic Medicine 27.5 (2024): 193.
Chicago
Liu, X., Liu, T., Wan, R."Clinical presentation of severe COVID‑19 with heart failure: A single‑center retrospective study". Experimental and Therapeutic Medicine 27, no. 5 (2024): 193. https://doi.org/10.3892/etm.2024.12481